Gathering and analyzing patient experience data in a real-world setting is a key challenge for many

By HEOR Staff Writer

January 18, 2023

Gathering and analyzing patient experience data in a real-world setting is a key challenge for many. To explore this further, ISPOR in Vienna held a second plenary panel featuring experts in the field. What did they discuss?

The panel discussed the importance of rigor in choosing, implementing, and analyzing patient experience data in non-randomized, uncontrolled study designs. Dr. Burgos spoke about the Darwin EU initiative and the importance of stakeholder engagement and capacity building to facilitate patient experience data collection. Professor Devlin discussed the implementation of patient-reported outcome data capture and the PROMs initiatives in the UK, Canada, and New Zealand. Dr. Perfetto spoke about the Core Impact initiative in the US, which standardizes patient experience data collection and the use of core outcome sets.

The panel highlighted the need for further guidance and collaboration with stakeholders to ensure patient experience data is used to inform regulatory decision-making.

Reference url

Recent Posts

Wegovy HD Approval: A Game Changer in Obesity Treatment and Weight Loss Efficacy

By João L. Carapinha

March 20, 2026

Novo Nordisk announced the Wegovy HD approval by the US Food and Drug Administration (FDA) for Wegovy® HD (semaglutide injection 7.2 mg), a higher-dose formulation showing superior weight loss over the existing 2.4 mg dose in adults with obesity. In the STEP UP trial, this new dose delivered an a...
Milestone Approval of Invasive Brain-Computer Interface Revolutionizes Spinal Cord Injury Treatment
China's National Medical Products Administration (NMPA) has approved the world's first invasive brain-computer interface medical device for market entry. Developed by Borui Kang Medical Technology (Shanghai) Co.,...
Accelerating Patient Access: MHRA NICE Alignment Initiative
MHRA NICE alignment introduces a groundbreaking pathway launching on 1 April 2026, synchronizing the Medicines and Healthcare products Regulatory Agency (MHRA)'s licensing with the National Institute for Health and Care Excellence (NICE)'s value assessments. This enables new medicines to reach pa...